THE HAEMOPHILIC PATIENT AND TRAVEL

In addition to the prevention of bleeding episodes, the introduction of self-infusion of coagulation factors in the late 1960s and early 1970s allowed patients with haemophilia to travel relying less on their physician or treatment centre and with greater safety while travelling. New haemophilia treatment options prevent physical disability and increase the mobility of haemophilia patients by allowing them to become full members of our mobile society, with an increasing desire to travel the world just like healthy individuals.

But what is the relationship between haemophilia and travel?

One study looked at the travel behaviour of patients with haemophilia A or B. The vast majority of people with haemophilia (about 98%) have travelled at least once since receiving their diagnosis. In addition, about 60% travel more than once a year (“frequent travellers”) and 37% travel outside of Europe (“long-haul travellers”).

Among the variables specific to haemophilia, self-infusion of coagulation factors is the most important for an increased likelihood of long-haul travel. While among patients aged 17 years and younger, not being on permanent prophylactic treatment is associated with an increased likelihood of long-haul travel  .

Other variables tested, including severity of haemophilia when compared between severe and moderate/mild, do not, however, appear to have any influence on the travel behaviour of adult haemophilia patients.

 

Reference:

  • Juergen Ringwald, Pamela Rudolph, Melanie Biner, Cornelia Fießler, Andreas Mayr, Martin Lohmann, Julian Strobel, Reinhold Eckstein, Karin Kurnik, Travel behaviour of patients with haemophilia, Travel Medicine and Infectious Disease (2013) 11, 159e165, http://dx.doi.org/10.1016/j.tmaid.2013.03.008
Back to news and insights

Wikiphilia

Learn more about the meaning of the words you read on this page and learn about the entire glossary on hemophilia.

The process by which the medicinal product passes from the point of administration into the plasma, by crossing biological membranes.

In the case of factor VIII, administration is via the intravenous route, which makes absorption immediate.

A protein belonging to the clotting factor category, a group of enzymes involved in the blood-clotting process.

It is encoded by a gene on the long arm of the X chromosome.

Factor VIII is also known as anti-haemophilic factor (AHF).

Product containing a high concentration of freeze-dried factor VIII, used for replacement therapy in the treatment of haemophilia A.

A ereditary genetic illness, characterised by a deficiency of clotting factor VIII, that exposes the individual to a greater risk of both internal and external bleeds.

Haemophilia A is more common in males, whereas females tend to be healthy carriers of the condition.

The typical symptoms of the condition include haemarthroses (joint bleeds) and haematomas (muscle bleeds).

The series of chemical changes that the medicinal product undergoes inside the body.

Condition that occurs when factor VIII activity is between 1% and 5%.

Condition that occurs when factor VIII activity is between 1% and 5%.

Condition that occurs when factor VIII activity is <1%.